Compare Sana Biotechnology Inc (SANA) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wipro Limited — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while Wipro Limited trades at $1.69 (market cap $17.95B). The key difference: Wipro Limited is far larger — about 17.4× Sana Biotechnology Inc's market cap, and Wipro Limited pays a 5.01% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | WIT | |
|---|---|---|
Market Cap | $1.03B | $17.95B |
Sector | Health | Technology |
52-Week High | $5.92 | $3.06 |
52-Week Low | $2.68 | $1.68 |
Enterprise Value | $946.04M | $16.02B |
Dividend Yield | — | 5.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
WIT trades at $1.73, down 4.42% today, with bearish technical signals and mixed earnings performance. Recent quarters show earnings misses against expectations, though the company maintains strong profitability with 13.92% net margin and 16.09% ROE. Positive business developments include renewed partnerships with ABB and Databricks to enhance digital and AI services.
The outlook is cautious due to earnings volatility and bearish analyst sentiment, with only 19% buy ratings. Risks include competitive pressures and macroeconomic uncertainty affecting tech spending. The stock's valuation appears reasonable with P/E of 12.98, but investor confidence hinges on improved earnings consistency and margin stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
